Esketamine hydrochloride in the management of moderate-to-severe depressive symptoms in patients undergoing multiple wound repair surgeries: A multi-centre randomized, double-blind, placebo-controlled trial.
Xiaomeng Yu, Tianqi Shen, Ting Zhang, Rui Bao, Ziyi Guo, Zirui Feng, Li Tong, Xiaoying Zhang, Mingzi Ran, Guanyong Sun, Weidong Mi, Jingsheng Lou, Qiang Fu
Clinical and translational medicine March 1, 2026 DOI: 10.1002/ctm2.70641 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Multi-centre, randomized, double-blind, placebo-controlled trial Peer reviewed |
|---|---|
| Sample size | 130 |
| Population | Adult patients undergoing multiple wound repair surgeries |
| Intervention | Esketamine |
| Dose | 0.2-0.3 mg/kg |
| Duration | Intraoperative administration; outcomes assessed on postoperative days 1-3 and up to 30 days for adverse events |
| Measures | MADRS, PHQ-9, HADS-A, YMRS, CADSS, BPRS |
| Topics | Esketamine |
| Keywords | Multiple trauma Postoperative complications Postoperative depression |
| Key findings | Intraoperative low-dose esketamine significantly increased response and remission rates for depressive symptoms on postoperative days 1-3 compared to placebo, without increasing neuropsychiatric adverse events. |
Abstract
Patients undergoing multiple wound repair surgeries often develop moderate-to-severe anxiety and depression. However, there is a lack of effective rapid emotional intervention strategies during the perioperative period. This multi-centre, randomized, double-blind, placebo-controlled trial involved 130 adult patients (65 in the esketamine group and 65 in the placebo group). Participants were randomly assigned to receive either esketamine (0.2-0.3 mg/kg) or saline intravenously during surgery. The primary outcome was the response rate (proportion of patients with ≥50% reduction in MADRS total score from baseline) on postoperative days (PODs) 1-3, evaluated using the Montgomery-Åsberg depression rating scale (MADRS). The secondary outcome was the remission rate (proportion of patients with MADRS total score ≤10) on postoperative days (PODs) 1-3; scores on the Patient Health Questionnaire-9 (PHQ-9), the Hospital Anxiety and Depression Scale-Anxiety subscale (HADS-A); and esketamine-related neuropsychiatric adverse events assessed using the Young Mania Rating Scale (YMRS), Clinician-Administered Dissociative States Scale (CADSS), and Brief Psychiatric Rating Scale (BPRS) within 30 days after surgery. The esketamine group showed a significantly higher response rate than the placebo group on POD 1-3. (POD 1: 53.8% vs. 26.2%, p = 0.001; POD 2: 60.0% vs. 40.0%, p = 0.009; POD 3: 73.8% vs. 53.8%, p = 0.018). The esketamine group also showed a higher remission rate and lower MADRS scores (POD 1: 33.8% vs. 10.8%, p = 0.002; POD 2: 40.0% vs. 23.1%, p = 0.038; POD 3: 56.9% vs. 23.1%, p < 0.001). Esketamine improved HADS-A and PHQ-9 scores by POD 3 without increasing neuropsychiatric adverse events within 30 days postoperatively. The results demonstrate that the intraoperative use of low-dose esketamine can rapidly and effectively alleviate moderate-to-severe anxiety and depressive symptoms in the early postoperative period (POD 1-3) among patients requiring repeated debridement surgeries without increasing neuropsychiatric or systemic adverse events within 30 days after surgery.
Comparable studies
Other randomized controlled trials on esketamine, most cited first.
Citations in the library
Cites 7
- NMDAR inhibition-independent antidepressant actions of ketamine metabolites Nature April 24, 2016
- Ketamine: 50 Years of Modulating the Mind Frontiers in Human Neuroscience November 29, 2016
- Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent The Journal of Clinical Psychiatry May 11, 2020
- Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories Psychological Medicine February 12, 2016
- Do the dissociative side effects of ketamine mediate its antidepressant effects? Journal of Affective Disorders February 18, 2014
and 2 more in the library